She has served as lead investigator and author for trials investigating novel nutrient-stimulated hormone (NuSH)-based therapies for obesity including dual hormone receptor agonist, tirzepatide, a GIP/GLP-1 receptor agonist (Jastreboff, et al ., NEJM , 2022 and NEJM , 2024), triple hormone receptor agonist, retatrutide, a GIP/GLP-1/Glucagon receptor agonist (Jastreboff, et al ., NEJM , 2023), and a monthly monoclonal antibody peptide conjugate, maridebart cafraglutide, a GIP receptor antagonist GLP-1 receptor agonist (Jastreboff, et, al., NEJM, 2025)
Isolation and characterization of gallic acid and methyl gallate from the seed coats of Givotia rottleriformis Griff
Likewise, some hypothesize that low testosterone in women influences libido
Efficacy of coenzyme Q10 in patients with cardiac failure: a meta-analysis of clinical trials
As the journey unfolds, semaglutide has opened a new chapter in the comprehensive approach to well-being, offering hope for individuals navigating the complexities of weight management and metabolic health
.png)
